BR112022023377A2 - Preparação e purificação de igg hipersialilada - Google Patents

Preparação e purificação de igg hipersialilada

Info

Publication number
BR112022023377A2
BR112022023377A2 BR112022023377A BR112022023377A BR112022023377A2 BR 112022023377 A2 BR112022023377 A2 BR 112022023377A2 BR 112022023377 A BR112022023377 A BR 112022023377A BR 112022023377 A BR112022023377 A BR 112022023377A BR 112022023377 A2 BR112022023377 A2 BR 112022023377A2
Authority
BR
Brazil
Prior art keywords
hypersialylated
igg
purification
preparation
purifying
Prior art date
Application number
BR112022023377A
Other languages
English (en)
Portuguese (pt)
Inventor
Schaeck John
Graham Steffen
Zouaoui Radouane
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BR112022023377A2 publication Critical patent/BR112022023377A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022023377A 2020-05-19 2021-05-19 Preparação e purificação de igg hipersialilada BR112022023377A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026875P 2020-05-19 2020-05-19
PCT/US2021/033156 WO2021236769A1 (en) 2020-05-19 2021-05-19 Preparation and purification of hypersialylated igg

Publications (1)

Publication Number Publication Date
BR112022023377A2 true BR112022023377A2 (pt) 2022-12-20

Family

ID=78708028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023377A BR112022023377A2 (pt) 2020-05-19 2021-05-19 Preparação e purificação de igg hipersialilada

Country Status (11)

Country Link
US (1) US20230193339A1 (https=)
EP (1) EP4153617A4 (https=)
JP (1) JP2023526527A (https=)
KR (1) KR20230012560A (https=)
CN (1) CN115715296A (https=)
AU (1) AU2021275117A1 (https=)
BR (1) BR112022023377A2 (https=)
CA (1) CA3182023A1 (https=)
CO (1) CO2022018364A2 (https=)
MX (1) MX2022014520A (https=)
WO (1) WO2021236769A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022023334A2 (pt) * 2020-05-19 2022-12-20 Momenta Pharmaceuticals Inc Imunoglobulina hipersialilada

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
PH12012502193A1 (en) * 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
AU2011290672B2 (en) * 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2877589B1 (en) * 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2935610A4 (en) * 2012-12-20 2016-08-31 Medimmune Llc METHODS OF USING ION EXCHANGE CHROMATOGRAPHY TO CONTROL GLYCOFORM RATES WITH HIGH MANNOSIS
WO2014144621A2 (en) * 2013-03-15 2014-09-18 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
CN104327180A (zh) * 2013-07-23 2015-02-04 天士力制药集团股份有限公司 一种重组人血小板衍生生长因子bb的纯化方法

Also Published As

Publication number Publication date
JP2023526527A (ja) 2023-06-21
CA3182023A1 (en) 2021-11-25
CN115715296A (zh) 2023-02-24
AU2021275117A1 (en) 2022-12-01
CO2022018364A2 (es) 2022-12-30
EP4153617A1 (en) 2023-03-29
MX2022014520A (es) 2023-03-03
KR20230012560A (ko) 2023-01-26
EP4153617A4 (en) 2024-11-20
US20230193339A1 (en) 2023-06-22
WO2021236769A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2019011554A (es) Purificacion de ficobiliproteinas.
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
CO2018004090A2 (es) Anticuerpos anti-tigit y métodos de uso
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
MX391043B (es) Formulaciones de anticuerpo y metodos.
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
EA201891724A1 (ru) Антитела к tgf-бета2
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
BR112018075667A2 (pt) cromatografia de interação hidrofóbica para purificação de oligonucleotídeos
CL2025002941A1 (es) Anticuerpos anti-sirp-alfa.
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
BR112022023334A2 (pt) Imunoglobulina hipersialilada
MX2014006248A (es) Anticuerpos nonoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs).
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
MX2021004356A (es) Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
BR112022023377A2 (pt) Preparação e purificação de igg hipersialilada
CL2023001137A1 (es) Procedimiento para la purificación de pleuromutilinas
AR120794A1 (es) Composiciones purificadas de enterovirus y métodos de purificación con cromatografía de afinidad con glutatión
CL2021000902A1 (es) Método para la fabricación de gemas sintéticas.
BR112017016110A2 (pt) composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus
EA202191779A1 (ru) Способ получения антраниламидов